1. Home
  2. RA vs NUVB Comparison

RA vs NUVB Comparison

Compare RA & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RA
  • NUVB
  • Stock Information
  • Founded
  • RA 2016
  • NUVB 2018
  • Country
  • RA United States
  • NUVB United States
  • Employees
  • RA N/A
  • NUVB N/A
  • Industry
  • RA Investment Managers
  • NUVB Biotechnology: Pharmaceutical Preparations
  • Sector
  • RA Finance
  • NUVB Health Care
  • Exchange
  • RA Nasdaq
  • NUVB Nasdaq
  • Market Cap
  • RA N/A
  • NUVB 679.9M
  • IPO Year
  • RA N/A
  • NUVB N/A
  • Fundamental
  • Price
  • RA $13.16
  • NUVB $1.75
  • Analyst Decision
  • RA
  • NUVB Strong Buy
  • Analyst Count
  • RA 0
  • NUVB 6
  • Target Price
  • RA N/A
  • NUVB $8.33
  • AVG Volume (30 Days)
  • RA 280.8K
  • NUVB 2.9M
  • Earning Date
  • RA 01-01-0001
  • NUVB 03-06-2025
  • Dividend Yield
  • RA 14.73%
  • NUVB N/A
  • EPS Growth
  • RA N/A
  • NUVB N/A
  • EPS
  • RA N/A
  • NUVB N/A
  • Revenue
  • RA N/A
  • NUVB $7,873,000.00
  • Revenue This Year
  • RA N/A
  • NUVB $47.99
  • Revenue Next Year
  • RA N/A
  • NUVB $551.81
  • P/E Ratio
  • RA N/A
  • NUVB N/A
  • Revenue Growth
  • RA N/A
  • NUVB N/A
  • 52 Week Low
  • RA $11.89
  • NUVB $1.66
  • 52 Week High
  • RA $17.32
  • NUVB $3.97
  • Technical
  • Relative Strength Index (RSI)
  • RA 40.51
  • NUVB 34.21
  • Support Level
  • RA $13.12
  • NUVB $1.85
  • Resistance Level
  • RA $13.32
  • NUVB $2.04
  • Average True Range (ATR)
  • RA 0.07
  • NUVB 0.12
  • MACD
  • RA 0.01
  • NUVB -0.01
  • Stochastic Oscillator
  • RA 31.25
  • NUVB 13.74

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Share on Social Networks: